The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Karl-Fredrik Eriksson

Associate professor

Default user image.

Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test

Author

  • Yang De Marinis
  • Torgny Sunnerhagen
  • Pradeep Bompada
  • Anna Bläckberg
  • Runtao Yang
  • Joel Svensson
  • Ola Ekström
  • Karl Fredrik Eriksson
  • Ola Hansson
  • Leif Groop
  • Isabel Gonçalves
  • Magnus Rasmussen

Summary, in English

The coronavirus disease 2019 (COVID-19) pandemic has created a global health- and economic crisis. Detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19 by serological methods is important to diagnose a current or resolved infection. In this study, we applied a rapid COVID-19 IgM/IgG antibody test and performed serology assessment of antibody response to SARS-CoV-2. In PCR-confirmed COVID-19 patients (n = 45), the total antibody detection rate is 92% in hospitalized patients and 79% in non-hospitalized patients. The total IgM and IgG detection is 63% in patients with <2 weeks from disease onset; 85% in non-hospitalized patients with >2 weeks disease duration; and 91% in hospitalized patients with >2 weeks disease duration. We also compared different blood sample types and suggest a higher sensitivity by serum/plasma over whole blood. Test specificity was determined to be 97% on 69 sera/plasma samples collected between 2016-2018. Our study provides a comprehensive validation of the rapid COVID-19 IgM/IgG serology test, and mapped antibody detection patterns in association with disease progress and hospitalization. Our results support that the rapid COVID-19 IgM/IgG test may be applied to assess the COVID-19 status both at the individual and at a population level.

Department/s

  • Genomics, Diabetes and Endocrinology
  • EXODIAB: Excellence of Diabetes Research in Sweden
  • Infection Medicine (BMC)
  • Translational infection medicine
  • Clinical Chemistry, Malmö
  • Division of Clinical Chemistry and Pharmacology
  • LUBIN Lab- Lund Brain Injury laboratory for Neurosurgical research
  • Cardiovascular Research - Translational Studies

Publishing year

2020

Language

English

Publication/Series

Infection Ecology and Epidemiology

Volume

10

Issue

1

Document type

Journal article

Publisher

Taylor & Francis

Topic

  • Infectious Medicine
  • Clinical Laboratory Medicine

Keywords

  • antibody test
  • COVID-19
  • disease severity and duration
  • IgM and IgG
  • SARS-CoV-2
  • serology assessment

Status

Published

Project

  • Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test

Research group

  • Genomics, Diabetes and Endocrinology
  • Translational infection medicine
  • Clinical Chemistry, Malmö
  • LUBIN Lab- Lund Brain Injury laboratory for Neurosurgical research
  • Cardiovascular Research - Translational Studies

ISBN/ISSN/Other

  • ISSN: 2000-8686